Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
NCT06540833 is registered in ClinicalTrials.gov with Intra-Cellular Therapies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 15, 2024
- Completion date
- December 29, 2028
- Enrollment
- 370 (estimated)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.